Is Metformin an SGLT2 Inhibitor or Something Else?

Metformin is not an SGLT2 inhibitor. It belongs to a completely different drug class called biguanides, and it lowers blood sugar through mechanisms that have nothing to do with how SGLT2 inhibitors work. The confusion is understandable because both drugs treat type 2 diabetes, are taken as pills, and increasingly appear side by side in treatment guidelines. But they target different organs, produce different side effects, and offer somewhat different benefits beyond glucose control.

How Metformin Actually Works

Metformin’s primary target is the liver. Your liver constantly produces glucose, even when you already have plenty circulating in your blood. In people with type 2 diabetes, this glucose production runs too high. Metformin dials it back by activating an enzyme called AMPK, which tells liver cells to slow down their glucose-manufacturing machinery.¹ The result is less sugar being dumped into your bloodstream between meals and overnight.

That liver effect is the headline mechanism, but metformin does more than just one thing. In the gut, it changes how glucose is absorbed, boosts the release of a hormone called GLP-1 that helps regulate blood sugar after meals, and even reshapes the population of bacteria living in your intestines.² Researchers are still sorting out how much each of these gut effects contributes to the drug’s overall benefit. Metformin also modestly improves how sensitive your muscles are to insulin, though this effect is considered secondary.

None of this involves the kidneys filtering out extra sugar, which is exactly what sets metformin apart from SGLT2 inhibitors.

How SGLT2 Inhibitors Work

SGLT2 inhibitors take an entirely different approach. They target a transporter protein in the kidneys that normally reclaims glucose from your urine before it leaves the body. This transporter handles about 90% of the glucose your kidneys reabsorb.³ By blocking it, SGLT2 inhibitors cause your body to excrete excess glucose through urination. You literally pee out sugar that would otherwise stay in your blood.

This mechanism is insulin-independent, meaning it works regardless of whether your pancreas is producing enough insulin or whether your cells are responding to it properly. Common SGLT2 inhibitors include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). They all end in “-gliflozin,” which is a quick way to recognize the drug class.

Because the kidney-based mechanism also flushes out calories in the form of glucose, SGLT2 inhibitors tend to cause weight loss on top of lowering blood sugar. They also have a mild diuretic effect, reducing blood pressure slightly. These secondary effects have turned out to matter a great deal for heart and kidney health.

Why People Confuse the Two

Part of the confusion stems from the fact that both drugs are oral medications for type 2 diabetes that are often prescribed together. Guidelines have increasingly placed them in similar positions in treatment algorithms, and doctors sometimes start one while continuing the other. When you hear your doctor mention both drugs in the same conversation, it can sound like they are interchangeable options rather than complementary tools that do fundamentally different things.

Another source of mix-ups is that both metformin and SGLT2 inhibitors activate some of the same cellular energy-sensing pathways, including AMPK, though they do so through different routes and in different tissues.⁴ At the molecular level, there are some overlapping downstream effects, but the primary site of action and the clinical profile of each drug are distinct.

Blood Sugar and Weight Effects Compared

Both drugs lower blood sugar effectively, but they do it through different organs and to somewhat different degrees depending on the patient. When researchers compared them head to head, the two drug classes showed broadly similar reductions in HbA1c, the standard measure of average blood sugar over the previous two to three months.⁵ Neither class clearly outperforms the other on raw glucose-lowering ability in most comparisons.

Weight is where SGLT2 inhibitors have a more consistent edge. Because they cause the body to excrete glucose (and the calories it carries), SGLT2 inhibitors typically lead to about two to three kilograms of weight loss over six to twelve months.⁶ Metformin can also cause modest weight loss or at least prevent weight gain, but the effect is smaller and less predictable. For people with type 2 diabetes who are also trying to lose weight, this difference can influence which drug a doctor emphasizes.

Using Both Together

Because metformin and SGLT2 inhibitors lower blood sugar through completely different mechanisms, combining them makes pharmacological sense. A meta-analysis of randomized trials found that the combination produced a larger drop in HbA1c than either drug alone, beating metformin monotherapy by roughly half a percentage point and SGLT2 inhibitor monotherapy by a similar margin.⁷ The combination also led to greater weight reduction compared to either drug by itself.⁸

In clinical practice, metformin is often the foundation of a treatment regimen, and an SGLT2 inhibitor is added on top of it when blood sugar targets are not being met or when a patient has additional risk factors for heart or kidney disease. Some newer guidelines have also considered starting both drugs at the same time, particularly for patients who are diagnosed with notably elevated blood sugar levels.

Cardiovascular Benefits

The heart is where the two drugs diverge most meaningfully. SGLT2 inhibitors have built a strong reputation for reducing the risk of hospitalization for heart failure. In a large cohort study comparing first-line users of the two classes, SGLT2 inhibitor initiators had a lower risk of hospitalization for heart failure and a numerically lower risk of heart attack compared to metformin initiators, though the combined risk of heart attack, stroke, and death was similar between the two groups.⁹

A separate analysis echoed the finding that SGLT2 inhibitors reduced heart attack and heart failure hospitalization risk, though safety profiles between the two classes were largely similar apart from a higher rate of genital infections with SGLT2 inhibitors.¹⁰ That said, in patients with lower cardiovascular risk, the advantage may be less clear. A nationwide cohort study looking specifically at patients without high cardiovascular risk found that SGLT2 inhibitor-based regimens and metformin-based regimens produced similar rates of death, cardiovascular death, hospitalization for heart failure, stroke, and kidney failure progression.¹¹

This is an important nuance. The cardiovascular edge of SGLT2 inhibitors appears most meaningful for people who already have heart disease or are at elevated risk for it. For someone with newly diagnosed type 2 diabetes and no cardiovascular complications, the case for choosing one over the other on heart grounds alone is weaker.

Kidney Protection

Both drugs have shown some ability to protect kidney function, but their mechanisms for doing so differ. SGLT2 inhibitors reduce the workload on the kidneys by lowering the amount of glucose being filtered, which decreases pressure inside the kidney’s filtering units. This effect has been validated in large trials, and SGLT2 inhibitors are now recommended for patients with chronic kidney disease regardless of whether they have diabetes.

Metformin has traditionally been viewed with caution in kidney disease because it can accumulate to dangerous levels when the kidneys cannot clear it properly. But recent evidence suggests that when kidney function is not severely impaired, metformin itself may offer some kidney-protective benefits. A randomized trial comparing metformin to empagliflozin (a common SGLT2 inhibitor) found that both drugs slowed the decline in kidney filtration rate compared to a control group, and both lowered a marker of kidney damage.¹²

The strongest evidence for kidney outcomes may come from combining the two drugs. A real-world study of patients already on an SGLT2 inhibitor found that those who also took metformin had a substantially lower risk of kidney disease progression and death compared to those on an SGLT2 inhibitor alone.¹³ This suggests the two drugs may complement each other for kidney protection, not just blood sugar control.

Side Effects Worth Knowing About

The everyday side effects of each drug reflect their different mechanisms. Metformin’s most common complaints are gastrointestinal: nausea, diarrhea, and stomach discomfort, especially when starting the drug or increasing the dose. These can usually be managed by ramping up the dose slowly over several weeks.¹⁴ SGLT2 inhibitors, on the other hand, tend to cause genital yeast infections and urinary tract infections, a predictable consequence of dumping sugar into the urinary tract where microbes can feast on it.

Both drugs carry rare but serious metabolic risks that work in different ways. Metformin is associated with a condition called lactic acidosis, in which lactic acid builds up in the blood to dangerous levels. This is uncommon with normal kidney function and appropriate dosing, but it can be life-threatening when it occurs. SGLT2 inhibitors carry a risk of euglycemic diabetic ketoacidosis, a form of ketoacidosis where blood sugar may look normal or only mildly elevated even though the body is producing dangerously high levels of ketones.¹⁵ The “euglycemic” part is especially tricky because patients and even some clinicians may not suspect ketoacidosis when blood sugar readings are not dramatically high. Both conditions require different emergency treatments, and when a patient takes both drugs simultaneously, clinicians need to consider the possibility of either or both.

Cost, Access, and Shifting Guidelines

Metformin has been available as a generic for decades and costs very little, often just a few dollars per month. SGLT2 inhibitors are considerably more expensive, though generic versions of some are beginning to appear in certain markets. The price gap raises a practical question: for patients in the early stages of type 2 diabetes who do not yet have heart or kidney complications, does the added benefit of an SGLT2 inhibitor justify the added cost?

Recent updates to the American Diabetes Association’s standards of care have shifted toward recommending SGLT2 inhibitors (and GLP-1 receptor agonists) earlier in treatment, particularly for patients with cardiovascular or renal risk.¹⁶ But some researchers have pushed back on this trend, pointing out that clinical evidence showing SGLT2 inhibitors are actually superior to metformin in patients without those complications remains scarce.¹⁷ For a large proportion of people newly diagnosed with type 2 diabetes, metformin remains the most cost-effective starting point, and switching to or adding an SGLT2 inhibitor makes the most sense when specific risk factors emerge.

Globally, the cost issue is even more stark. In low- and middle-income countries where diabetes is surging, metformin’s affordability makes it the backbone of treatment. SGLT2 inhibitors are largely inaccessible in these settings, which means metformin will remain the default first-line therapy in much of the world for the foreseeable future regardless of what American or European guidelines recommend.

Beyond Diabetes

Both drug classes have attracted research attention for uses beyond blood sugar control, though in different directions. Metformin has a long history of off-label use in polycystic ovary syndrome (PCOS), where it helps with insulin resistance and can restore menstrual regularity. It has also been studied extensively in cancer prevention and is the subject of a major clinical trial investigating whether it can slow aging itself.

SGLT2 inhibitors have also been explored in PCOS, where a meta-analysis found they improved body weight, fasting glucose, and insulin resistance.¹⁸ Their most dramatic expansion, however, has been into heart failure and chronic kidney disease, where they are now prescribed even for people who do not have diabetes at all. This is something metformin has not achieved; its approved indications remain tied to diabetes and related metabolic conditions.

Aging Research and Shared Cellular Pathways

One of the more intriguing parallels between the two drugs is their potential role in aging biology. Metformin has been studied for its possible anti-aging effects for over a decade, largely because of observations that people with diabetes taking metformin sometimes had lower rates of age-related diseases than people without diabetes. The TAME (Targeting Aging with Metformin) trial is designed to test whether metformin can delay the onset of age-related conditions in older adults without diabetes.

More recently, SGLT2 inhibitors have entered the aging conversation. Both drug classes appear to influence cellular pathways involved in aging, including energy regulation through AMPK, autophagy (the process by which cells clean up damaged components), free radical production, and inflammation.⁴ Whether these shared molecular effects translate into meaningful anti-aging benefits in humans is still an open question. The research is early, and most of the evidence comes from animal models and mechanistic studies rather than long-term human trials. But the overlap is striking enough that some researchers have speculated about whether combining the two drugs might produce synergistic effects on aging-related biology, not just on blood sugar.

For now, that remains firmly in the realm of hypothesis rather than clinical recommendation. But it helps explain why both drugs keep showing up in the same research circles despite being pharmacologically distinct. They arrived at some of the same biological crossroads from completely different starting points.